Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 12/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL876625 | 0.89 | SCN9A (0.49) | ARSCN9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL9360272 | 0.83 | AR (0.56) | ARSCN9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL875802 | 0.82 | CYP1A2 (0.46) | ARSCN9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL875742 | 0.82 | AR (0.49) | ARSCN9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL22719774 | 0.81 | AR (0.50) | ARCYP1A2CYP2C9CYP2C19RECQL | |
| SCHEMBL29558965 | 0.81 | AR (0.50) | ARCYP1A2CYP2C9CYP2C19RECQL | |
| SCHEMBL24998725 | 0.81 | FNTA (0.49) | ARSCN9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL875952 | 0.81 | SCN9A (0.47) | ARSCN9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL9900777 | 0.80 | AR (0.44) | ARSCN9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL30360761 | 0.79 | AR (0.56) | ARCYP1A2CYP2C9CYP2C19RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LTD (GB) | 2014-12-25 | — | — | US | disclosed |
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LTD (GB) | 2014-12-25 | — | — | US | disclosed |
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LTD (GB) | 2014-12-25 | — | — | US | disclosed |
| US-8871928-B2 | Tricyclic compounds, preparation methods, and their uses | GLAXO GROUP LIMITED (GB) | 2014-10-28 | — | — | US | disclosed |
| US-8871928-B2 | Tricyclic compounds, preparation methods, and their uses | GLAXO GROUP LIMITED (GB) | 2014-10-28 | — | — | US | disclosed |
| US-8871928-B2 | Tricyclic compounds, preparation methods, and their uses | GLAXO GROUP LIMITED (GB) | 2014-10-28 | — | — | US | disclosed |
| EP-2619203-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | Glaxo Group Limited (GB) | 2013-07-31 | — | — | EP | disclosed |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| WO-2012037782-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012037782-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | LIPG, PCSK9, ENPP2 | AR 3517/4885SCN9A 4613/4885CYP1A2 2190/4885 |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | LIPG, PCSK9, ENPP2 | AR 3517/4885SCN9A 4613/4885CYP1A2 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.